Wayfair Inc vs Zimmer Biomet Holdings Inc — how do they compare? Wayfair Inc trades at $84.81 (market cap $11.58B), while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Zimmer Biomet Holdings Inc is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays a 1.07% dividend while Wayfair Inc pays none. Which is the better fit depends on your goals.
| W | ZBH | |
|---|---|---|
Market Cap | $11.58B | $17.36B |
Sector | Consumer Cyclical | Health |
52-Week High | $119.05 | $107.71 |
52-Week Low | $56.42 | $79.58 |
Enterprise Value | $14.16B | $24.40B |
Dividend Yield | — | 1.07% |
Signals from Pluang's Aura AI — not financial advice
Wayfair (W) trades at $87.76, down 1.74% today, showing mixed technical signals with a neutral overall rating. The company continues to face profitability challenges with negative net income margins (-2.41%) despite strong revenue growth to $12.46 billion in 2025. Recent earnings performance has been inconsistent, with a Q2 2026 miss after previous beats. Analyst sentiment remains positive with 52% buy ratings and a $93.58 consensus target, while the company expands into physical retail and leverages AI capabilities.
The stock presents a growth story with improving operational cash flow and market share gains in e-commerce, but faces significant execution risks from high debt levels (95% debt-to-asset ratio) and persistent unprofitability. Current valuation at 0.89 P/S appears reasonable for the sector, though the elevated EV/EBITDA of 110.6 signals premium pricing expectations. Near-term catalysts include the July Black Friday sale and brick-and-mortar expansion, but macroeconomic pressures on housing remain a headwind.
Zimmer Biomet (ZBH) trades at $88.92, down 2.41% on the day, with a bearish technical signal but strong fundamentals including a 70.03% gross margin and three consecutive quarterly EPS beats. Revenue grew to $8.23B in 2025, though net income margin compressed to 8.56%. The company announced a $1 billion share repurchase increase and expansion in India, while maintaining a dividend.
The stock offers a 10% upside to the $97.67 consensus price target, supported by value metrics and operational strength, but faces risks from rising debt levels and competitive pressures. Analyst sentiment is mixed with 40% buy ratings, suggesting cautious optimism amid near-term technical weakness.
Trailing returns across standard periods
Latest headlines on both assets
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →